Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia – the role of busulfan pharmacokinetics in determining outcome

Bone Marrow Transplantation volume 36, pages 839–845 (2005)Cite this article

Summary:

In total, 94 patients with homozygous beta thalassemia were randomized to two different conditioning regimens: busulfan 600 mg/m2+cyclophosphamide 200 mg/kg or busulfan 16 mg/kg+cyclophosphamide 200 mg/kg and antilymphocyte globulin (47 in each group), for bone marrow transplantation, to see whether increased myeloablation or increased immunosuppression would reduce rejection. Busulfan pharmacokinetics in determining outcome was evaluated. There was no significant difference in engraftment, graft-versus-host disease, rejection, and overall and disease-free survival in the two groups. Systemic exposure to busulfan was significantly higher in the 600 mg/m2 group, but in both groups there was a wide interindividual variation in the busulfan kinetics. Six patients rejected the graft, two in the busulfan 600 mg group and four in busulfan 16 mg group (P=0.677 CI −0.17, 0.07), but in five patients (pharmacokinetic data not available in one patient) who rejected the graft busulfan first dose trough level (Cmin-1) was below 150 ng/ml while it was above this level in the 66 of 68 patients with successful engraftment (P⩽0.001). This randomized trial shows that rejection is influenced by busulfan levels and suggests that monitoring of busulfan levels and dose adjustment based on first-dose kinetics may reduce the risk of rejection.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Galimberti M, Angelucci E, Baroncianni D et al. Bone marrow transplantation in thalasemia. The experience of Pesaro. Bone Marrow Transplant 1997; 19 (Suppl. 2): 45–47.

    Google Scholar 

  2. Schrier SL, Angelucci E . New strategies in the treatment of the thalassemias. Ann Rev Med 2005; 56: 157–171.

    Article  CAS  PubMed  Google Scholar 

  3. Ball LM, Lankester AC, Giordano PC et al. Paediatric allogeneic bone marrow transplantation for homozygous beta-thalassaemia, the Dutch experience. Bone Marrow Transplant 2003; 31: 1081–1087.

    Article  CAS  PubMed  Google Scholar 

  4. Shing MM, Yuen PM, Li CK et al. A more immunosuppressive pre-transplant conditioning may be required for Chinese patients with thalassaemia. Bone Marrow Transplant 1996; 17: 907–910.

    CAS  PubMed  Google Scholar 

  5. Poonkuzhali B, Srivastava A, Quernin MH et al. Pharmacokinetics of oral busulfan in children with beta thalassemia major undergoing allogeneic bone marrow transplantation. Bone marrow Transplant 1999; 24: 5–11.

    Article  CAS  PubMed  Google Scholar 

  6. Hassan M, Fasth A, Gerritsen B et al. Busulfan kinetics and limited sampling model in children with leukemia and inherited disorders. Bone Marrow Transplant 1996; 18: 843–850.

    CAS  PubMed  Google Scholar 

  7. Vassal G, Deroussent A, Challine D et al. Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 1992; 79: 2475–2479.

    CAS  PubMed  Google Scholar 

  8. Storb R, Blume KG, O’Donnell MR et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Blood Marrow Transplant 2001; 7: 39–44.

    Article  CAS  Google Scholar 

  9. Chandy M, Srivastava A, Dennison D et al. Allogeneic bone marrow transplantation in the developing world: experience from a center in India. Bone Marrow Transplant 2001; 27: 785–790.

    Article  CAS  PubMed  Google Scholar 

  10. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft versus host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  PubMed  Google Scholar 

  11. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562–1568.

    Article  CAS  PubMed  Google Scholar 

  12. Jones RJ, Lee KSK, Beschorner WE et al. Venocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778–783.

    Article  CAS  PubMed  Google Scholar 

  13. Quernin MH, Poonkuzhali B, Medard Y et al. High-performance liquid chromatographic method for quantification of busulfan in plasma after derivatization by tetrafluorothiophenol. J Chromatogr 1999; 721: 147–152.

    Article  CAS  Google Scholar 

  14. Quernin MH, Poonkuzhali B, Montes C et al. Quantification of busulfan in plasma by Gas chromatography-mass spectrometry. J Chromatogr 1998; 709: 47–56.

    Article  CAS  Google Scholar 

  15. Heinzel G, Woloszezak R, Thoman P . Pharmacokinetic Pharmacodynamic Data Analysis System for the PC. Gustav Fischer: Sturtgart, Germany, 1993.

    Google Scholar 

  16. Thomas ED, Buckner CD, Sanders JE et al. Marrow transplantation for thalassaemia. Lancet 1982; 2: 227.

    Article  CAS  PubMed  Google Scholar 

  17. Lucarelli G, Andreani M, Angelucci E . The cure of thalassemia by bone marrow transplantation. Blood Rev 2002; 16: 81–85.

    Article  CAS  PubMed  Google Scholar 

  18. Chen YC, Lin KH, Huang WS, Tang JL . Bone marrow transplantation in Taiwan: an overview. Bone Marrow Transplant 1994; 13: 907–910.

    Google Scholar 

  19. Lawson SE, Roberts IA, Amrolia P et al. Bone marrow transplantation for beta-thalassaemia major: the UK experience in two paediatric centres. Br J Haematol 2003; 120: 289–295.

    Article  PubMed  Google Scholar 

  20. Iannone R, Casella JF, Fuchs EJ et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant 2003; 9: 519–528.

    Article  PubMed  Google Scholar 

  21. Sodani P, Gaziev D, Polchi P et al. A new approach for bone marrow transplantation in class 3 thalassemic patients aged less than 17 years. Blood 2004; 104: 1201–1203.

    Article  CAS  PubMed  Google Scholar 

  22. Brachet C, Azzi N, Demulder A et al. Hydroxyurea treatment for sickle cell disease: impact on hematopoietic stem cell transplantation outcome. Bone Marrow Transplant 2004; 33: 799–803.

    Article  CAS  PubMed  Google Scholar 

  23. Storb R, Etzioni R, Anasetti C et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994; 84: 941–949.

    CAS  PubMed  Google Scholar 

  24. Vassal G, Fischer G, Challine D et al. Busulfan disposition below the age of three: alteration in children with lysosomal storage disease. Blood 1993; 82: 1030–1034.

    CAS  PubMed  Google Scholar 

  25. Hassan M, Ljungman P, Bolme P et al. Busulfan bioavailability. Blood 1994; 84: 2144–2150.

    CAS  PubMed  Google Scholar 

  26. Shaw PJ, Scharping CE, Brian RJ, Earl JW . Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood 1994; 84: 2357–2362.

    CAS  PubMed  Google Scholar 

  27. Yeager AM, Wagner JE, Graham ML et al. Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 1992; 80: 2425–2428.

    CAS  PubMed  Google Scholar 

  28. Slattery JT, Sanders JE, Buckner CD et al. Graft rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16: 31–42.

    CAS  PubMed  Google Scholar 

  29. Slattery JT, Clift RA, Buckner CD et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89: 3055–3060.

    CAS  PubMed  Google Scholar 

  30. McCune JS, Gooley T, Gibbs JP et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 30: 167–173.

    Article  CAS  PubMed  Google Scholar 

  31. Pawlowska AB, Blazar BR, Angelucci E et al. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia. Bone Marrow Transplant 1997; 20: 915–920.

    Article  CAS  PubMed  Google Scholar 

  32. Grochow LB, Jones RJ, Brundrett RB et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55–61.

    Article  CAS  PubMed  Google Scholar 

  33. Dix SP, Wingard JR, Mullins RE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225–230.

    CAS  PubMed  Google Scholar 

  34. Anderson BS, Thall PF, Madden T et al. Busulfan systemic exposure relative to regimen related toxicity and acute graft versus host disease: defining a therapeutic window for IV BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002; 8: 477–485.

    Article  CAS  Google Scholar 

  35. Ljungman P, Hassan M, Bekassy AN et al. Busulfan concentration in relation to permanent alopecia in recipients of bone marrow transplants. Bone Marrow Transplantation 1995; 15: 869–871.

    CAS  PubMed  Google Scholar 

  36. Srivastava A, Poonkuzhali B, Shaji RV et al. Glutathione S-transferase M1 polymorphism – a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 2004; 104: 1574–1577.

    Article  CAS  PubMed  Google Scholar 

  37. Bleyazac N, Souillet G, Magron P et al. Reduced transplant related mortality by Bayesian individualization of busulfan dosage in children. Bone Marrow Transplant 2001; 28: 743–751.

    Article  Google Scholar 

  38. Demirer T, Buckner CD, Appelbaum FR et al. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant 1996; 17: 341–346.

    CAS  PubMed  Google Scholar 

  39. Dupuis LL, Najdova M, Saunders EF . Retrospective appraisal of busulfan dose adjustment in children. Bone Marrow Transplant 2000; 26: 1143–1147.

    Article  CAS  PubMed  Google Scholar 

  40. McCune JS, Gibbs JP, Slattery JT . Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet 2000; 39: 155–165.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported in part by the Indian Council of Medical Research grant towards the project ‘Advanced Center for Bone Marrow Transplantation for Thalassaemia in India’ (56/2/93-BMS II).

Author information

Authors and Affiliations

  1. Department of Hematology, Christian Medical College, Vellore, India

    M Chandy, P Balasubramanian, S V Ramachandran, V Mathews, B George & A Srivastava

  2. Sultan Qaboos University Hospital, Muscat, Oman

    D Dennison

  3. INSERM, U458, Hospital Robert Debre, Paris, France

    R Krishnamoorthy

Authors
  1. M Chandy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Balasubramanian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S V Ramachandran
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V Mathews
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B George
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Dennison
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Krishnamoorthy
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Srivastava
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Chandy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chandy, M., Balasubramanian, P., Ramachandran, S. et al. Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia – the role of busulfan pharmacokinetics in determining outcome. Bone Marrow Transplant 36, 839–845 (2005). https://doi.org/10.1038/sj.bmt.1705151

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705151

Keywords

This article is cited by

Search

Advanced search

Quick links